Neurolentech Signs Technology Access Partnership With Kaerus Bioscience
Neurolentech recently announced a technology access partnership with Kaerus Bioscience, a biotechnology company committed to turning scientific advances into treatment realities for patients with rare genetic syndromes of neurodevelopment. The agreement enables Kaerus Bioscience to access Neurolentech’s NDD Drug Discovery platform and leverage its proprietary cell models and assays for functional screens to drive advances in neurodevelopmental disorders research.
Built for NDD drug discovery, Neurolentech’s Platform comprises a vast collection of human-derived neuronal cell lines from patients with monogenic and complex neurodevelopmental disorders. The Platform will enable Kaerus Bioscience to model the complex neural networks underlying clinical features of genetic NDDs at a cellular level, as well as to investigate the therapeutic potential of its small molecule pipeline for numerous genetic syndromes preclinically.
The partnership marks a significant milestone in Neurolentech’s mission to advance drug discovery for NDDs, and further reinforces its NDD Drug Discovery platform as a valuable resource for both researchers and industry partners.
Fiona Nielsen, CEO of Neurolentech, said “We are excited to collaborate with Kaerus Bioscience in advancing their programs in the field of neurodevelopmental disorders. Our platform’s unique capabilities offer unparalleled insights into disease mechanisms, facilitating the development of novel therapies.”
Robert Ring, CEO of Kaerus Bioscience, added “Our partnership with Neurolentech underscores Kaerus’ commitment to leveraging cutting-edge technology and innovative platform approaches to accelerating the discovery of treatments for patients with genetic disorders of neurodevelopment.”
Neurolentech is a biotech startup doing drug discovery for epilepsy and related genetic neurodevelopmental disorders (NDDs). The Neurolentech drug discovery platform is built on a library of human-derived iPSCs and hIPSC-derived neuronal cell models from patients across the epilepsy and NDD spectrum. Neurolentech has developed unique proprietary assays for interrogating the molecular aspects and cellular functional mechanisms of disease. With the combination of patient-derived models and assays optimized for interrogating NDD related mechanisms, Neurolentech can discover novel targets for drug discovery and screen effectiveness of potential novel therapeutics across their unique library of patient-derived models. For more information, visit http://neurolentech.com.
Kaerus Bioscience Ltd is a biotechnology company committed to turning scientific advances into treatment realities for patients with rare genetic syndromes of neurodevelopment. Kaerus has developed a pipeline of targeted, small-molecule therapeutics that address an underlying ion channel dysfunction in Fragile X syndrome, the most common inherited cause of intellectual disability and autism globally. For more information, visit www.kaerusbio.com.
Total Page Views: 475
